Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

NCT02216084 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02216084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02216084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
February 22, 2016
Enrollment
16 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary thrombotic thrombocytopenic purpura (ttp)